Pleiotropic Effects of Alpha-Lipoic Acid in Treatment of Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus

Abstract

INTRODUCTION: Type 2 diabetes mellitus is an urgent problem due to its widespread prevalence and disability of patents in result of macro- and microvascular complications. Diabetic neuropathy (DN) considerably impairs the quality of life of patients. Use of alpha-lipoic acid (ALA) prevents the development of oxidative stress and improves oxidation of fatty acids.

AIM: To study the influence of alpha-lipoic acid on the variability of glycemia, lipid spectrum, ‘positive’ and ‘negative’ neurological symptoms in patients with DM2 and DN.

MATERIALS AND METHODS: The prospective study included 39 patients with DM2 and DN in the clinical stage: patients of group 1 (n = 20) were administered intravenous drip infusion of ALA 600 mg once a day for 2 weeks in hospital conditions followed by intake of 600 mg once a day per os for 2.5 months on an outpatient basis; patients of group 2 (n = 19) did not receive ALA preparations. In all the patients, parameters of lipid and carbohydrate metabolism were studied, pain, tactile, temperature, vibration sensitivity and muscle strength of lower extremities were evaluated.

RESULTS: In patients of group 1, after 12 weeks of using ALA, decrease in ‘positive’ symptoms in the lower legs and feet, improvement in vibration (0.6 ± 0.5 points, p = 0.0095), tactile (0.7 ± 0.6 points, p = 0.037), temperature sensitivity (0.2 ± 0.4 points, p = 0.027), and also decrease in the average value of glycemia (8.7 [7.4; 9.2] mmol/l, p = 0.0078), decrease in glycated hemoglobin with the achievement of the target value (7.5 ± 0.1%, p = 0.046) and improvement of lipid spectrum (total cholesterol — 5.9 ± 0.1 mmol/ l, p = 0.043) were recorded; low density lipoproteins — 3.6 ± 0.1 mmol/l, p = 0.0076; high density lipoproteins — 1.2 ± 0.1 mmol/l, p = 0.034).

CONCLUSION: In patients with type 2 diabetes mellitus with diabetic neuropathy in the clinical stage who received preparations of alpha-lipoic acid in complex treatment, reduction of neurologic deficit, of ‘positive’ neurologic symptoms was achieved in 12 weeks; with that, improvement of lipid spectrum and of glycemic control was found, which may be considered as pleiotropic effects associated with acceleration of mitochondrial biosynthesis.

Keywords

type 2 diabetes mellitus / diabetic neuropathy / alpha-lipoic acid

References

[1] Galstyan GR, Shestakova EA, Sklyanik IA. Obesity and type 2 diabetes: can we find a compromised treatment solution? Diabetes Mellitus. 2017;20(4):270–8. (In Russ). doi: 10.14341/DM8726

[2] Галстян Г.Р., Шестакова Е.А., Скляник И.А. Ожирение и сахарный диабет 2 типа: поиск компромиссного терапевтического лечения // Сахарный диабет. 2017. Т. 20, № 4. С. 270–278. doi: 10.14341/DM8726

[3] IDF Diabetes Atlas [Internet]. Available at: https://diabetesatlas.org/resources/. Accessed: 2022 August 29.

[4] IDF Diabetes Atlas [Internet]. Доступно по: https://diabetesatlas.org/resources/. Ссылка активна на 29.08.2022.

[5] Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes Mellitus. 2017;20(1):13–41. (In Russ). doi: 10.14341/DM8664

[6] Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета // Сахарный диабет. 2017. Т. 20, № 1. С. 13–41. doi: 10.14341/DM8664

[7] Kalinin RE, Suchkov IA, Mzhavanadze ND, et al. Regenerative technologies in treatment of diabetic foot ulcers. Genes & Cells. 2017;12(1):15–26. (In Russ). doi: 10.23868/201703002

[8] Калинин Р.Е., Сучков И.А., Мжаванадзе Н.Д., и др. Регенеративные технологии в лечении синдрома диабетической стопы // Гены & Клетки. 2017. Т. 12, № 1. С. 15–26. doi: 10.23868/201703002

[9] Kalinin RE, Suchkov IA, Deev RV, et al. Possibilities of combined approach for treatment of critical limb ischemia of lower extremities in diabetic patients. Bulletin of Pirogov National Medical & Surgical Center. 2018;13(2):12–7. (In Russ).

[10] Калинин Р.Е., Сучков И.А., Деев Р.В., и др. Возможности комбинированного подхода к лечению пациентов с критической ишемией нижних конечностей при фоновом сахарном диабете // Вестник Национального медико-хирургического Центра им. Н.И. Пирогова. 2018. Т. 13, № 2. С. 12–17.

[11] Kotskaya AV, Salaychuk EV, Kudinov VI, et al. Variability of arterial pressure and cardiac rhythm in patients with coronary heart disease and diabetes mellitus: Effect of sodium-glucose co-transporter 2 inhibitor. I. P. Pavlov Russian Medical Biological Herald. 2021;29(4):489–96. (In Russ). doi: 10.17816/PAVLOVJ72376

[12] Коцкая А.В., Салайчук Е.В., Кудинов В.И., и др. Вариабельность артериального давления и ритма сердца у больных с ишемической болезнью сердца и сахарным диабетом, влияние ингибитора натрийглюкозного ко-транспортера 2 типа // Российский медико-биологический вестник имени академика И.П. Павлова. 2021. Т. 29, № 4. С. 489–496. doi: 10.17816/PAVLOVJ72376

[13] Ametov AS, Kosyan AA, Pashkova EYu, et al. The advantage of using complex therapy for diabetic polyneuropathy in patients with type 2 diabetes mellitus. Endocrinology: News, Opinions, Training. 2019;8(3):8–21. (In Russ). doi: 10.24411/2304-9529-2019-13001

[14] Аметов А.С., Косян А.А., Пашкова Е.Ю., и др. Преимущества применения комплексной терапии диабетической полиневропатии у пациентов с сахарным диабетом 2 типа // Эндокринология: Новости. Мнения. Обучение. 2019. Т. 18, № 3. С. 8–21. doi: 10.24411/2304-9529-2019-13001

[15] Tanashyan MM, Antonova KV, Raskurazhev AA. Diabetic polyneuropathy: pathogenesis, clinical presetation and new approaches to personalized treatment. Medical Council. 2017;(17):72–80. (In Russ). doi: 10.21518/2079-701X-2017-17-72-80

[16] Танашян М.М., Антонова К.В., Раскуражев А.А. Диабетическая полинейропатия: патогенез, клиника, подходы к персонифицированной коррекции // Медицинский совет. 2017. № 17. С. 72–80. doi: 10.21518/2079-701X-2017-17-72-80

[17] Kalinin RE, Suchkov IA, Klimentova EA, et al. Influence of Combined Antioxidant Therapy on Results of Endovascular Treatment of Patients with Peripheral Arterial Disease. Nauka Molodykh (Eruditio Juvenium). 2022;10(4):401–12. (In Russ). doi: 10.23888/HMJ2022104401-412

[18] Калинин Р.Е., Сучков И.А., Климентова Э.А., и др. Влияние применения комбинированной антиоксидантной терапии на результаты эндоваскулярного лечения пациентов с облитерирующим атеросклерозом артерий нижних конечностей // Наука молодых (Eruditio Juvenium). 2022. Т. 10, № 4. С. 401–412. doi: 10.23888/HMJ2022104401-412

[19] Fernández–Galilea M, Pérez–Matute P, Prieto–Hontoria PL, et al. α-Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects. Biochimica et Biophysica Acta. 2015;1851(3):273–81. doi: 10.1016/j.bbalip.2014.12.013

[20] Fernández–Galilea M., Pérez–Matute P., Prieto–Hontoria P.L., et al. α-Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/ obese subjects // Biochimica et Biophysica Acta. 2015. Vol. 1851, No. 3. P. 273–281. doi: 10.1016/j.bbalip.2014.12.013

[21] Le Garf S, Sibille B, Mothe–Satney I, et al. Alpha-lipoic acid supplementation increases the efficacy of exercise- and diet-induced obesity treatment and induces immunometabolic changes in female mice and women. FASEB Journal. 2021;35(4):e21312. doi: 10.1096/fj.202001817RR

[22] Le Garf S., Sibille B., Mothe–Satney I., et al. Alpha-lipoic acid supplementation increases the efficacy of exercise- and diet-induced obesity treatment and induces immunometabolic changes in female mice and women // FASEB Journal. 2021. Vol. 35, No. 4. P. e21312. doi: 10.1096/fj.202001817RR

[23] Laptev DN. Relationship of hypoglycemia and glucose variability with autonomic dysfunction in children and adolescents with type 1 diabetes. Diabetes Mellitus. 2014;17(4):87–93. (In Russ). doi: 10.14341/DM2014487-92

[24] Лаптев Д.Н. Связь гипогликемии и вариабельности гликемии с автономной дисфункцией у детей и подростков с сахарным диабетом 1 типа // Сахарный диабет. 2014. Т. 17, № 4. C. 87–93. doi: 10.14341/DM2014487-92

[25] Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 1 in adults. Diabetes Mellitus. 2020;23(S1):42–114. (In Russ). doi: 10.14341/DM12505

[26] Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Сахарный диабет 1 типа у взрослых // Сахарный диабет. 2020. Т. 23, № S1. C. 42–114. doi: 10.14341/DM12505

[27] Ziegler D. Sovremennyye printsipy vedeniya bol’nykh s diabeticheskoy polineyropatiyey. Nervno-Myshechnyye Bolezni. 2012;(2): 7–20. (In Russ). doi: 10.17650/2222-8721-2012-0-2-7-19

[28] Ziegler D. Современные принципы ведения больных с диабетической полинейропатией // Нервно-мышечные болезни. 2012. № 2. C. 7–19. doi: 10.17650/2222-8721-2012-0-2-7-19

[29] Mendoza–Núñez VM, García–Martínez BI, Rosado–Pérez J., et al. The Effect of 600 mg Alpha-lipoic Acid Supplementation on Oxidative Stress, Inflammation, and RAGE in Older Adults with Type 2 Diabetes Mellitus. Oxidative Medicine and Cellular Longevity. 2019;2019:3276958. doi: 10.1155/2019/3276958

[30] Mendoza–Núñez V.M., García–Martínez B.I., Rosado–Pérez J., et al. The Effect of 600 mg Alpha-lipoic Acid Supplementation on Oxidative Stress, Inflammation, and RAGE in Older Adults with Type 2 Diabetes Mellitus // Oxidative Medicine and Cellular Longevity. 2019. Vol. 2019. P. 3276958. doi: 10.1155/2019/3276958

[31] Solmonson A, De Berardinis RJ. Lipoic acid metabolism and mitochondrial redox regulation. The Journal of Biological Chemistry. 2018;293(20):7522–30. doi: 10.1074/jbc.TM117.000259

[32] Solmonson A., De Berardinis R.J. Lipoic acid metabolism and mitochondrial redox regulation // The Journal of Biological Chemistry. 2018. Vol. 293, No. 20. P. 7522–7530. doi: 10.1074/jbc.TM117.000259

[33] Mahmoudi–Nezhad M, Vajdi M, Farhangi MA. An updated systematic review and dose-response meta-analysis of the effects of α-lipoic acid supplementation on glycemic markers in adults. Nutrition. 2021;82:111041. doi: 10.1016/j.nut.2020.111041

[34] Mahmoudi–Nezhad M., Vajdi M., Farhangi M.A. An updated systematic review and dose-response meta-analysis of the effects of α-lipoic acid supplementation on glycemic markers in adults // Nutrition. 2021. Vol. 82. P. 111041. doi: 10.1016/j.nut.2020.111041

[35] Jeffrey S, Samraj PI, Raj BS. The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials. Current Diabetes Reviews. 2021;17(9):e011821190404. doi: 10.2174/1573399817666210118145550

[36] Jeffrey S., Samraj P.I., Raj B.S. The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials // Current Diabetes Reviews. 2021. Vol. 17, No. 9. P. e011821190404. doi: 10.2174/1573399817666210118145550

[37] Agathos E, Tentolouris A, Eleftheriadou I, et al. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. The Journal of International Medical Research. 2018;46(5): 1779–90. doi: 10.1177/0300060518756540

[38] Agathos E., Tentolouris A., Eleftheriadou I., et al. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy // The Journal of International Medical Research. 2018. Vol. 46, No. 5. P. 1779–1790. doi: 10.1177/0300060518756540

[39] Lazarte J, Hegele RA. Dyslipidemia Management in Adults With Diabetes. Canadian Journal of Diabetes. 2020;44(1):53–60. doi: 10.1016/j.jcjd.2019.07.003

[40] Lazarte J., Hegele R.A. Dyslipidemia Management in Adults With Diabetes // Canadian Journal of Diabetes. 2020. Vol. 44, No. 1. P. 53–60. doi: 10.1016/j.jcjd.2019.07.003

RIGHTS & PERMISSIONS

Eco-Vector